OrganoClick AB (ORGC) AI Stock Analysis

0 Followers

OrganoClick AB

(Nasdaq OMX AB:ORGC)

Select Model

Rating:48Neutral

Price Target:SEK 0.48▼(-1.02% Downside)

Action:reiterated

Date:10/28/26

The score is held down primarily by weak financial performance: declining revenue, deep losses, high leverage versus a small equity base, and ongoing negative cash flow. Technicals provide partial offset with improving medium-term momentum (price above 20/50/100-day averages), though longer-term trend remains below the 200-day average and momentum is nearing overbought levels. Valuation offers limited support due to negative earnings and no indicated dividend yield.

Positive Factors

Proprietary green-chemistry platformThe proprietary organocatalysis platform gives OrganoClick a defined technology base for developing bio-based alternatives to fossil-derived and hazardous chemicals. Its relevance across functional material treatments may support differentiated products and continued commercial development over the next several quarters.

Negative Factors

Declining revenueRevenue contraction indicates that OrganoClick is not currently converting its product and technology offering into expanding sales. A sustained decline can reduce operating leverage, limit investment capacity, and make it harder for the company to absorb fixed costs while pursuing commercialization.

OrganoClick AB (ORGC) vs. iShares MSCI Sweden ETF (EWD)

Market Cap: SEK 96.74M
Dividend Yield: ―
Average Volume (3M): 265.46K
Price to Earnings (P/E): -1.6
Beta (1Y): 0.88
Revenue Growth: -21.95%
EPS Growth: -28.77%
Country: Sweden
Employees: 33
Sector: Basic Materials
Sector Strength: 61
Industry: Chemicals - Specialty

OrganoClick AB Business Overview & Revenue Model

Company Description

OrganoClick AB (publ), a technology firm based in Täby, Sweden, was established in 2006. The company specializes in the development, production, and sale of innovative fiber-based materials and chemicals for applications spanning wood treatment, tech...

OrganoClick AB Financial Statement Overview

Summary

Weak overall fundamentals: revenue declined ~8% TTM and profitability remains deeply negative (EBIT margin ~-30%, net margin ~-36%). Balance sheet risk is elevated with very high leverage (debt ~78.6m vs equity ~10.5m; ~7.5x debt-to-equity) and eroding equity. Cash flow remains negative (OCF ~-4.0m; FCF ~-7.3m) despite some improvement in cash burn versus the prior year.

Income Statement

22Negative

Balance Sheet

18Very Negative

Cash Flow

24Negative

Financial statement breakdown
Breakdown	TTM	Dec 2025	Dec 2024	Dec 2023	Dec 2022	Dec 2021
Income Statement
Total Revenue	90.28M	106.19M	127.23M	145.87M	115.05M	110.06M
Gross Profit	14.11M	14.86M	31.84M	35.39M	12.94M	18.51M
EBITDA	-9.27M	-12.80M	5.71M	5.95M	-21.19M	-12.92M
Net Income	-32.19M	-36.37M	-17.97M	-15.77M	-41.62M	-31.03M
Balance Sheet
Total Assets	136.75M	135.22M	126.98M	150.75M	162.86M	188.39M
Cash, Cash Equivalents and Short-Term Investments	480.00K	2.68M	538.00K	10.74M	15.20M	34.25M
Total Debt	78.56M	77.78M	51.67M	62.39M	61.68M	53.54M
Total Liabilities	121.59M	114.81M	89.15M	97.34M	95.30M	80.66M
Stockholders Equity	10.53M	15.18M	28.98M	44.58M	58.78M	100.33M
Cash Flow
Free Cash Flow	-7.35M	-10.51M	-5.51M	-8.08M	-35.35M	-52.34M
Operating Cash Flow	-4.03M	-8.29M	3.60M	533.00K	-21.22M	-37.69M
Investing Cash Flow	-9.91M	-10.99M	-9.11M	-8.61M	-7.45M	-14.65M
Financing Cash Flow	12.08M	21.42M	-4.69M	3.60M	9.63M	54.56M

OrganoClick AB Technical Analysis

Technical Analysis SentimentPositive

Last Price0.49

Price Trends

50DMA0.31Positive

100DMA0.37Positive

200DMA0.72Negative

Market Momentum

MACD0.06Negative

RSI63.46Neutral

STOCH38.38Neutral

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For SE:ORGC, the sentiment is Positive. The current price of 0.49 is above the 20-day moving average (MA) of 0.35, above the 50-day MA of 0.31, and below the 200-day MA of 0.72, indicating a neutral trend. The MACD of 0.06 indicates Negative momentum. The RSI at 63.46 is Neutral, neither overbought nor oversold. The STOCH value of 38.38 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for SE:ORGC.

OrganoClick AB Peers Comparison

Overall Rating

UnderperformOutperform

Sector (61)

Financial Indicators

SE:ORGC against its peers
Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
SE:PCAT	69Neutral	SEK 17.98M	4.54	―	―	-17.14%	88.76%
SE:HPOL.B	68Neutral	SEK 32.27B	18.14	12.33%	4.41%	-0.82%	-7.46%
Sector *	61Neutral	$10.43B	7.12	-0.05%	2.87%	2.86%	-36.73%
SE:ORGC	48Neutral	SEK 96.74M	-1.62	-176.65%	―	-21.95%	-28.77%
SE:NEXAM	40Underperform	SEK 249.06M	-12.16	-9.37%	―	-4.57%	-15.20%
SE:POLYG	40Underperform	SEK 93.14M	-22.05	-1.52%	―	-18.26%	35.77%
SE:AERO	28Underperform	SEK 23.82M	-0.53	-87.92%	―	-11.55%	60.56%

* Basic Materials Sector Average

Performance Comparison

SE:ORGC and its peers over the selected period
Ticker	Company Name	Price	Change	% Change
SE:ORGC	OrganoClick AB	0.49	-1.20	-71.07%
SE:HPOL.B	Hexpol AB	95.25	16.03	20.24%
SE:NEXAM	Nexam Chemical Holding AB	2.48	-0.57	-18.69%
SE:AERO	Svenska Aerogel Holding AB	0.44	-0.92	-67.65%
SE:POLYG	Polygiene AB	2.63	-6.37	-70.78%
SE:PCAT	Photocat A/S	3.44	-0.36	-9.47%

Glossary

BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

Disclaimer

This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.

Date of analysis: Oct 28, 2026

OrganoClick AB AI Stock Analysis